ASH 2023 | The role of radioimmunoconjugates in AML treatment: insights from the SIERRA trial
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, shares promising findings from the SIERRA trial (NCT02665065), showing the benefit of the radioimmunoconjugate apamistamab followed by reduced intensity conditioning regimens in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), including those with TP53 mutations. He mentions this may be the beginning of a new era that utilizes radioimmunotherapy prior to transplantation in AML. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Amgen, Actinuum, Celgene/BMS, Omeros, Johnson & Johnson, Miltenyi, Takeda
Board of Directors/Advisory Committee: Amgen, Actinuum, Celgene/BMS, Kite Pharma, Janssen, Jazz Pharmaceuticals, Johnson & Johnson, Novartis, Spectrum Pharma, Takeda
